95 related articles for article (PubMed ID: 15539430)
1. Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression.
Burd CJ; Petre CE; Moghadam H; Wilson EM; Knudsen KE
Mol Endocrinol; 2005 Mar; 19(3):607-20. PubMed ID: 15539430
[TBL] [Abstract][Full Text] [Related]
2. A central domain of cyclin D1 mediates nuclear receptor corepressor activity.
Petre-Draviam CE; Williams EB; Burd CJ; Gladden A; Moghadam H; Meller J; Diehl JA; Knudsen KE
Oncogene; 2005 Jan; 24(3):431-44. PubMed ID: 15558026
[TBL] [Abstract][Full Text] [Related]
3. Specificity of cyclin D1 for androgen receptor regulation.
Petre-Draviam CE; Cook SL; Burd CJ; Marshall TW; Wetherill YB; Knudsen KE
Cancer Res; 2003 Aug; 63(16):4903-13. PubMed ID: 12941814
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor (AR) NH2- and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth.
Hsu CL; Chen YL; Ting HJ; Lin WJ; Yang Z; Zhang Y; Wang L; Wu CT; Chang HC; Yeh S; Pimplikar SW; Chang C
Mol Endocrinol; 2005 Feb; 19(2):350-61. PubMed ID: 15514032
[TBL] [Abstract][Full Text] [Related]
5. Domain interactions between coregulator ARA(70) and the androgen receptor (AR).
Zhou ZX; He B; Hall SH; Wilson EM; French FS
Mol Endocrinol; 2002 Feb; 16(2):287-300. PubMed ID: 11818501
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.
Dubbink HJ; Hersmus R; Pike AC; Molier M; Brinkmann AO; Jenster G; Trapman J
Mol Endocrinol; 2006 Aug; 20(8):1742-55. PubMed ID: 16627595
[TBL] [Abstract][Full Text] [Related]
7. Negative modulation of androgen receptor transcriptional activity by Daxx.
Lin DY; Fang HI; Ma AH; Huang YS; Pu YS; Jenster G; Kung HJ; Shih HM
Mol Cell Biol; 2004 Dec; 24(24):10529-41. PubMed ID: 15572661
[TBL] [Abstract][Full Text] [Related]
8. An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP).
He B; Bai S; Hnat AT; Kalman RI; Minges JT; Patterson C; Wilson EM
J Biol Chem; 2004 Jul; 279(29):30643-53. PubMed ID: 15107424
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.
Burd CJ; Petre CE; Morey LM; Wang Y; Revelo MP; Haiman CA; Lu S; Fenoglio-Preiser CM; Li J; Knudsen ES; Wong J; Knudsen KE
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2190-5. PubMed ID: 16461912
[TBL] [Abstract][Full Text] [Related]
10. An investigation into CAG repeat length variation and N/C terminal interactions in the T877A mutant androgen receptor found in prostate cancer.
Southwell J; Chowdhury SF; Gottlieb B; Beitel LK; Lumbroso R; Purisima EO; Trifiro M
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):138-46. PubMed ID: 18619542
[TBL] [Abstract][Full Text] [Related]
11. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor.
Dubbink HJ; Hersmus R; Verma CS; van der Korput HA; Berrevoets CA; van Tol J; Ziel-van der Made AC; Brinkmann AO; Pike AC; Trapman J
Mol Endocrinol; 2004 Sep; 18(9):2132-50. PubMed ID: 15178743
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex.
Rampalli S; Pavithra L; Bhatt A; Kundu TK; Chattopadhyay S
Mol Cell Biol; 2005 Oct; 25(19):8415-29. PubMed ID: 16166625
[TBL] [Abstract][Full Text] [Related]
13. The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor.
Powzaniuk M; McElwee-Witmer S; Vogel RL; Hayami T; Rutledge SJ; Chen F; Harada S; Schmidt A; Rodan GA; Freedman LP; Bai C
Mol Endocrinol; 2004 Aug; 18(8):2011-23. PubMed ID: 15131260
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.
Schiewer MJ; Morey LM; Burd CJ; Liu Y; Merry DE; Ho SM; Knudsen KE
Oncogene; 2009 Feb; 28(7):1016-27. PubMed ID: 19079343
[TBL] [Abstract][Full Text] [Related]
15. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity.
Petre CE; Wetherill YB; Danielsen M; Knudsen KE
J Biol Chem; 2002 Jan; 277(3):2207-15. PubMed ID: 11714699
[TBL] [Abstract][Full Text] [Related]
17. Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.
Minamiguchi K; Kawada M; Ohba S; Takamoto K; Ishizuka M
Mol Cell Endocrinol; 2004 Feb; 214(1-2):175-87. PubMed ID: 15062556
[TBL] [Abstract][Full Text] [Related]
18. The FXXLF motif mediates androgen receptor-specific interactions with coregulators.
He B; Minges JT; Lee LW; Wilson EM
J Biol Chem; 2002 Mar; 277(12):10226-35. PubMed ID: 11779876
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner.
Reutens AT; Fu M; Wang C; Albanese C; McPhaul MJ; Sun Z; Balk SP; Jänne OA; Palvimo JJ; Pestell RG
Mol Endocrinol; 2001 May; 15(5):797-811. PubMed ID: 11328859
[TBL] [Abstract][Full Text] [Related]
20. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2).
Berrevoets CA; Doesburg P; Steketee K; Trapman J; Brinkmann AO
Mol Endocrinol; 1998 Aug; 12(8):1172-83. PubMed ID: 9717843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
